Latest Can-Fite BioPharma News & Updates

See the latest news and media coverage for Can-Fite. We track all announcements, press releases, and industry mentions in real time, all in one place.

Can-Fite BioPharma (Can-Fite)

Biopharmaceutical developer of oral treatments for cancer, inflammatory, metabolic diseases

canfite.com

Number of employees: 5–10
Industry: Pharmaceuticals

Last updated October 1

Latest news about Can-Fite BioPharma (Can-Fite)

In short: Can-Fite reported extended survival in its pivotal liver cancer trial and advanced pancreatic, cirrhosis, psoriasis and financing milestones during 2026.

Company announcements

September 2 Can-Fite

Can-Fite observes extended survival in its pivotal liver cancer trial

The company will evaluate accelerating the planned interim analysis of the Namodenoson study due to these encouraging early results.

August 12 Can-Fite

Can-Fite highlights regulatory status of Phase III drug candidates

Namodenoson holds FDA Fast Track and orphan drug designations for liver cancer in the U.S. and Europe; Piclidenoson is also in Phase III for psoriasis.

August 3 Can-Fite

Can-Fite launches Piclidenoson clinical program for Lowe syndrome

Phase 2 study protocol submitted to Bambino Gesù Children's Hospital; aims to evaluate efficacy and safety in five adult patients.

July 20 Can-Fite

Can-Fite's Phase 2a pancreatic cancer data accepted at ESMO 2026

The Phase 2a study of Namodenoson met its primary safety endpoint and showed encouraging survival outcomes.

Media coverage

October 1 Substack

🚨 CANF: NAMODENOSON’S REMARKABLE 28-MONTH CIRRHOSIS STORY — A SEPTEMBER DEVELOPMENT INVESTORS SHOULD NOT IGNORE

Nothing contained herein is a recommendation to buy, sell, or hold Can-Fite BioPharma (CANF) or any other security.

September 9 Financial Times

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel...

September 8 RTTNews

Can-Fite Reports Q2 2026 Results As Liver Cancer Survival Exceeds Expectations

Can-Fite BioPharma Ltd. ( CANF) reported first-half 2026 financial results and clinical updates, highlighting longer-than-anticipated overall survival in its ongoing pivotal Phase III study of...

September 2 StocksToTrade

CANF Stock Jolted As $100M Shelf Registration Hits Tape

Can-Fite Biopharma Ltd’s stocks have been trading down by -17.93 percent amid heightened concern over its latest clinical ...

Never miss news about Can-Fite

Track Can-Fite and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Can-Fite competitors & trending companies

Browse news for competitors to Can-Fite and other trending companies.